Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica LSE:OXB London Ordinary Share GB00BDFBVT43 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.50p -0.39% 896.50p 889.50p 897.00p 920.00p 872.90p 900.20p 107,306 16:35:18
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 37.6 -11.8 -0.3 - 592.05

Oxford Biomedica Share Discussion Threads

Showing 106651 to 106673 of 106675 messages
Chat Pages: 4267  4266  4265  4264  4263  4262  4261  4260  4259  4258  4257  4256  Older
DateSubjectAuthorDiscuss
20/9/2018
19:30
Interesting view from Woodford on their CAR-T choice Autolus. Https://woodfordfunds.com/words/insights/wpct-interim-results-2018/
pharmaboy2
20/9/2018
16:15
I would love to see Trovax with a PD-1 HTTps://www.drugtargetreview.com/news/35232/anti-pd-l1-cancer-vaccine/ The researchers tested the vaccine design on mice with a form of notoriously aggressive melanoma. All mice in the experiment were given the anti-cancer therapy anti-PD-L1. The mice were then split into three group: eight received the cancer vaccine, eight received the cancer vaccine plus Diprovocim, and eight received the cancer vaccine plus an alternative adjuvant called alum. The researchers observed a 100 percent survival rate over 54 days in the mice given the cancer vaccine and Diprovocim. This was in contrast to a zero percent survival rate in mice given only the cancer vaccine and a 25 percent survival rate in mice given the cancer vaccine with alum. “It was exciting to see the vaccine working simultaneously with a cancer immunotherapy like anti-PD-L1,” says Prof Boger.
marcusl2
20/9/2018
15:40
HTTps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024700/ George Quote: Last, but not least, RetinoStat has been developed to tackle retinal neovascularization, which is associated to the age-related macular degeneration. Neovascularization is quenched physiologically by the angiostatic proteins expressed during the process of normal wound healing [143]. Based on this concept, RetinoStat contains two potently angiostatic genes, endostatin and angiostatin [111]. When subretinally injected in mice, rabbits, and macaques, RetinoStat efficiently abolished the retinal blood vessel proliferation [102,108,111]. This evidence opened the way for the first phase I clinical trial testing the safety of subretinal injection of a non-primate lentiviral vector in patients affected by neovascular age-related macular degeneration [116]. This study confirmed that not only RetinoStat provides robust and sustained expression of the bicistronic transgene, but it also helps to reduce the excess fluid characteristically residing in the neural retina of sick patients [116]. A complementary non-primate lentiviral platform, named EncorStat, has been more recently developed to minimize corneal neovascularization, which represents the most important risk factor for rejection following corneal transplantation [144]. To this purpose, the bicistronic organization of EncorStat allows the delivery of the same two angiostatic proteins synthesized by Retinostat [113]. Worth mentioning, rabbit corneas incubated with EncorStat before surgery significantly suppressed neovascularization in a rabbit model of corneal rejection, favouring the improvement of an ex vivo therapeutic protocol [113]. RetinoStat and EncorStat are only two recent examples testifying that the carrying capacity of lentiviral vectors may permit co-delivery of multiple genes. This aspect is of relevant interest for future clinical application, since it could facilitate multifaceted targeting of eye disorders with potentially greater therapeutic effects than single gene delivery approaches. Furthermore, beneficial outcomes could be extended to cell types not directly transduced by lentiviral vectors if, for example, a paracrine effect could be attained by a sufficient amount of a therapeutic protein secreted by adjacent transduced cells.
marcusl2
20/9/2018
15:36
Interesting re oncolytic vaccines like Trovax and Immune Design`s collection. The previous deal, in February, saw Merck & Co pay a 184% premium to take out Viralytics for $394m, though unlike Viratherapeutics this company had a phase II asset (Merck & Co makes biggest oncolytic virus bet since Amgen in 2011, February 21, 2018). True, Amgen’s 2011 buyout of the Imlygic originator Biovex for $424m is a long way from being declared a masterstroke, but the potential of oncolytic viruses in immuno-oncology combinations is now increasingly being talked about – specifically in terms of turning “cold” tumours “hot” – and indeed Boehringer says this dual approach is central to its cancer immunology research strategy. Ph3s will cost 69-8OMM. $ONCY will decide on a partner (M&A activities are vigorous!) or sell the company. Decision will be made in “real time”. Won’t need to wait till trial completion.
marcusl2
20/9/2018
12:13
A good report - which has spurred some into selling. Have I misread it?
icejelly
20/9/2018
12:01
This looks like it's gonna drift lower on profit taking. My previous pi55 taking 500 prediction was exactly that, but 750 is realistic. Waiting and watching
excellance
20/9/2018
11:48
Great report Taffy, thank you
gutterhead
20/9/2018
11:28
RSS Hardman & Co Research (OXB) Thursday 20 September, 2018 Hardman & Co Research Oxford BioMedica (OXB): Partnering strategy del... hTtps://www.investegate.co.uk/hardman--amp--co-research/eqs/oxford-biomedica--oxb---partnering-strategy-del---/20180920105501ETRDP/
taffy100
20/9/2018
11:09
However, in the high-dose cohort, all of the patients who were evaluated from 3 years onwards showed equivalent or improved scores relative to baseline at every time point. In conclusion, the new data demonstrate the long-term safety and promising efficacy profile of ProSavin in Parkinson's disease patients for up to 8 years of follow-up. These are the longest follow-up assessments reported in any Parkinson's disease gene therapy study. Although the results are encouraging, the data suggest that the optimal level of dopamine replacement may not have been achieved, since patients continued to require oral L-Dopa therapy to obtain maximal benefit, and some of the more severely affected patients required DBS 2–6 years following ProSavin administration. Further dose escalation using ProSavin would be challenging due to limitations on vector titers using current production processes and the volume of vector that can be safely administered into the human striatum. Therefore, a new vector (OXB-102) has been recently developed in which the configuration of three dopamine biosynthesis enzymes was further optimized to increase the capacity for dopamine production significantly compared to ProSavin.20 This vector is under preclinical development and, pending regulatory approval, will be assessed in a new Phase I/II study to determine the appropriate dose before a larger placebo-controlled Phase IIb clinical trial is undertaken. HTTps://www.liebertpub.com/doi/10.1089/humc.2018.081?platform=hootsuite&
marcusl2
20/9/2018
10:00
PH, Dr Grupp re allogeneic Off the shelf at 39 mins; "where the f..k are their clinical trials? I have a profound degree of scepticism. Allo may have a place if given 3 or 4 times over 4-6 months as a temporary fix." HTTps://slingshotinsights.com/projects/621 He was such a big critic that they wanted him on their side I guess $$$ talks. (51.30) This is the interview that he said 5T4 is a reasonable target for solid tumours but stuck in 1st gear. HTTps://slingshotinsights.com/projects/621
marcusl2
20/9/2018
09:38
Here you go Https://mobile.twitter.com/JacobPlieth/status/1042436884021092352/photo/2
pharmaboy2
20/9/2018
09:35
Sorry wrong chart 1949. Need coffee
pharmaboy2
20/9/2018
09:34
First time ive seen CAR-T and CRISP-R combined in same chart. One for the dynamic Trio ! Https://mobile.twitter.com/JacobPlieth/status/1039903394591371264/photo/1
pharmaboy2
20/9/2018
09:18
"We were surprised that NICE have not supported the 'end of life' criteria for this population of DLBCL patients and strongly disagree with this decision," the spokesperson said. All of NICE's cost-effectiveness estimates were above £40,000 per quality-adjusted life year (QALY), a commonly used value metric, with the "most plausible" ratio being "much more than £54,000 per QALY gained." NHS' normally acceptable range is between £20,000 and £30,000 per QALY gained. The reviewing committee also said Novartis did not make the case for Kymriah to be included in the Cancer Drugs Fund. Gilead will face a follow-up appraisal meeting Sept. 27. Novartis said it plans to work with NICE "to define the most relevant comparator studies and reconsider the 'end of life' decision." The cost agency said it also welcomes further discussions. NICE will accept comments and new evidence regarding the decision until Oct. 10. Its next committee meeting is set for Oct. 23. HTTps://www.biopharmadive.com/news/nice-says-no-to-kymriah-for-adult-lymphoma-despite-offer-on-price/532738/
marcusl2
20/9/2018
09:17
Significant personnel move in CAR-T world Https://uk.finance.yahoo.com/news/car-t-pioneer-dr-stephan-203000228.html
pharmaboy2
20/9/2018
09:06
Thanks for taking the time to do that Harry. I`d be delighted if we even make the average of those guesses. I have no doubt Novartis will get the deal with NICE eventually.
marcusl2
20/9/2018
08:31
To be fair that's mainly one person with a half empty outlook who has had the perpetually sliding target buyout price.Similarly, when 12p was the price to be released from this torture, there weren't the recent deals or the declared profits.
harry s truman
20/9/2018
07:27
I'm going to abstain from the price guessing game, but interesting to see the 'old money' prices - quite amazing that the lowest price on there is now 14p, when I recall some hoping for a takeover at 12p :-)
cottonpickers
19/9/2018
23:32
£16.53 £0.3306 Mr Roper £14.65 £0.2930 asat91 £13.75 £0.2750 old sage £13.74 £0.2748 HST £13.59 £0.2718 Gareth Jones £13.24 £0.2648 Antreg £13.05 £0.2610 bunlop £12.90 £0.2580 Northstand £12.75 £0.2550 SCRUTABLE £12.45 £0.2490 catch007 £12.40 £0.2480 ewads £12.31 £0.2462 timax333 £12.25 £0.2450 sharelog3 £12.10 £0.2420 gutterhead £12.00 £0.2400 dmorford1 £11.99 £0.2398 stcsnatter £11.85 £0.2370 fhasson £11.80 £0.2360 pharmaboy2 £11.50 £0.2300 2upthespurs £11.42 £0.2284 marcusl2 £11.33 £0.2266 trovax £11.24 £0.2248 greenas1953 £11.11 £0.2222 icejelly £10.80 £0.2160 PramBigear £10.60 £0.2120 sddavies1 £10.32 £0.2064 WiltshireRam £10.25 £0.2050 volsung £10.07 £0.2014 Jasierock £9.94 £0.1988 R0bT £9.77 £0.1954 BEANOL £9.40 £0.1880 Xia £9.20 £0.1840 Plutonian £7.00 £0.1400 LimaJane
harry s truman
19/9/2018
23:22
Apologies Pram, I'd missed that point in your post and then took the diversion direct to windbag city. At some point I'm sure it will all change when that inevitable breakthrough treatment becomes the new norm. The only question is just how long it actually takes.
harry s truman
19/9/2018
21:51
Well said Mr President but I did say using chemo with no alternative is forgivable.
prambigear
19/9/2018
20:35
Whilst I'm on a roll, just a quick one regarding the point about foreign aid. If any of you are due a long flight and like to read, then "confessions of an economic hitman" is quite a good memoir from a man who used to work in the government aid industry. The last chapter is a bit born again for me, but the life story prior to that was quite an eyeopener. I'll not spoil it, but even though it's an America-centric book (the author is American) it did explain the system very well.
harry s truman
19/9/2018
19:29
added the provisional schedule published today to the end of the header; note expected publication date of 23 January 2019
bountyhunter
Chat Pages: 4267  4266  4265  4264  4263  4262  4261  4260  4259  4258  4257  4256  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180920 22:37:50